Novavax Looks To Secondary Endpoints As Phase III RSV Vaccine Trial Fails
Executive Summary
Novavax’s shares plunged 67% on news that its Phase III trial for RSV had failed, but are there signs of life for the product?
You may also be interested in...
Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.
Novavax Succeeds In Phase III Flu Vaccine Trial Against Sanofi’s Fluzone
Phase III trial could lead to mid-2020 BLA filing to prevent seasonal influenza in adults 65 and older. Novavax also talked up the potential value of its adjuvant in COVID-19 vaccine development.
Enanta Hopes To Succeed In RSV With N-Protein Inhibition Approach
Enanta's N-protein inhibitor EDP-938 hit a pair of endpoints in a Phase IIa challenge study, but real-world testing may be a higher hurdle. The company believes its therapeutic approach is more effective than fusion protein prophylactic approaches.